CN105105143A - Health-care food composition capable of increasing bone density, health-care food and preparation method - Google Patents
Health-care food composition capable of increasing bone density, health-care food and preparation method Download PDFInfo
- Publication number
- CN105105143A CN105105143A CN201510446638.2A CN201510446638A CN105105143A CN 105105143 A CN105105143 A CN 105105143A CN 201510446638 A CN201510446638 A CN 201510446638A CN 105105143 A CN105105143 A CN 105105143A
- Authority
- CN
- China
- Prior art keywords
- health
- health food
- preparation
- care food
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 235000013305 food Nutrition 0.000 title claims abstract description 19
- 230000037182 bone density Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 21
- 235000013402 health food Nutrition 0.000 claims description 27
- 208000001132 Osteoporosis Diseases 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 235000009508 confectionery Nutrition 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 18
- 229910052791 calcium Inorganic materials 0.000 abstract description 18
- 210000000988 bone and bone Anatomy 0.000 abstract description 17
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 abstract description 12
- 239000001354 calcium citrate Substances 0.000 abstract description 12
- 210000003022 colostrum Anatomy 0.000 abstract description 12
- 235000021277 colostrum Nutrition 0.000 abstract description 12
- 235000013337 tricalcium citrate Nutrition 0.000 abstract description 12
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
- 230000004221 bone function Effects 0.000 abstract 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000008407 joint function Effects 0.000 abstract 1
- 210000000689 upper leg Anatomy 0.000 description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 239000011122 softwood Substances 0.000 description 4
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000011833 salt mixture Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001694 thigh bone Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101100513612 Microdochium nivale MnCO gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003718 vitamin K5 derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a health-care food composition capable of increasing a bone density, a health-care food and a preparation method. The health-care food composition comprises the following ingredients, by weight, 15-25 parts of glucosamine hydrochloride, 25-40 parts of calcium citrate, 5-25 parts of chondroitin sulfate and 0.5-3 parts of colostrum alkaline powder. When the health-care food composition is used for preparing health-care food, the absorption efficiency of calcium can be raised obviously, and bone and joint functions can be improved.
Description
Technical field
The invention belongs to field of health care food, be specifically related to a kind of health-care food composition, health food and preparation method thereof that increase bone density.
Background technology
Osteoporosis refers to the microstructure degeneration of bone amount minimizing, bone for principal character, so that the fragility of bone increases a kind of general osteopathy increased with risk of fractures frequency, is also common disease, the frequently-occurring disease of the elderly.Osteoporosis is generally divided into two large classes and primary sclerotin to dredge disease and secondary osteoporosis.Primary osteoporosis comprises idiopathic osteoporosis and degeneration osteoporosis.Secondly its clinical symptoms and sign mainly pain be height shortening, hunchback, fracture and Respiratory Disturbances.Osteoporosis refers to the microstructure degeneration of bone amount minimizing, bone for principal character, so that the fragility of bone increases a kind of general osteopathy increased with risk of fractures frequency, is also common disease, the frequently-occurring disease of the elderly.
The main pathogenesis of osteoporosis is that the bone remoulding of body is unbalance, and bone remoulding is that interactional one of osteoclast and Gegenbaur's cell had not only opposed but also unified cellular activity process.The protease of osteoclast secretion can digest the bone matrix protein as ossein.
According to the data of the World Health Organization, osteoporosis is global health problem, and seriousness is only second to cardiovascular disease.Ill consequence is pain, loses mobility, can't take care of oneself, also can caused death during burst.In more than the 50 years old personage in the whole world, 1/3 women threatens by osteoporosis, higher than breast cancer incidence; 1/5 male sex threatens, higher than prostate-cancer incidence by this disease.Annual women's osteoporotic fracture ratio, higher than the summation of heart disease, apoplexy and breast cancer.A statistics display for China's 5 regional more than 5000 examples more than 40 years old population, osteoporotic illness rate is 16.1%, suffers from osteoporosis in the old women of 60 years old-70 years old more than 20%.The women of more than 80 years old has nearly 2/3 to suffer from osteoporosis.And osteoporotic fracture be disable, lethal principal element.Along with the aggravation of social senilization's degree, in 50 years of future global osteoporotic fracture patients and all can significantly increase the financial burden that society causes.
Bone density is an important symbol of bone mass, reflection osteoporosis degree, the important evidence of prediction fracture risk.Human bone content of mineral substances and bone strength and homeostasis closely related, because of but the important indicator of appraiser's class health status.
Summary of the invention
The invention provides a kind of health-care food composition, health food and preparation method thereof that increase bone density, the health food prepared by this health-care food composition has to be convenient to absorb, and eutherapeutic advantage, especially has the efficacy effect increasing bone density.
Increase a food compositions for bone density, comprise the component of following weight portion:
In the present invention, aminoglucose hydrochloride can directly block protease in cartilage enzymatic activity, suppress to reduce super oxyradical produce, remedy the materials such as nonsteroidal anti-inflammatory agent to the infringement of cartilage cell, block cartilage destruction, stimulate the collagen in cartilage cell's synthesized human and hyaluronic acid, expedite the emergence of knuckle synovia, articular cartilage that reparation has been worn, and the effects such as new articular cartilage and synovial membrane can be generated; Impact when chondroitin sulfate can strengthen the cushioning ability in joint and relaxes walking or beat and friction, supply oxygen and nutrient is delivered to joint, helps to remove IA refuse; Calcium citrate can increase the intake of calcium, has importantly slow down effect to sclerotin loss; Colostrum basic protein fraction powder can promote osteoblastic propagation and differentiation, suppression osteoclast bone information, bon e formation in growth period had to spread effect, bone matrix is increased and bone tissue reinforcement, have effect to the suppression etc. of bone amount reduction.Result of the test shows, after this several active substance combination, toxicity is little, and can play and collaborative increase bone density, improve bone and function of joint.
Present invention also offers a kind of described health-care food composition and preparing the application in health food, described health food is used for prevention and improves osteoporosis.
This health food can be prepared into various formulation, such as granule, Tablet and Capsula agent.Consider from the angle being convenient to take, as preferably, described health food is tablet, comprises active component and the auxiliary material of following weight portion:
As preferably, described filler is that the sweet mellow wine of 0.4 ~ 0.8:1 and lactose form by mass ratio.Wherein, sweet mellow wine has cooling feeling and pleasantly sweet when orally-dissolvable, without sand type, comparatively be suitable for preparing chewable tablets, lactose stable in properties, can with most drug compatibility and not chemically reactive, no hygroscopicity, select both to coordinate the drug-eluting of the tablet obtained as filler fast, taste and outward appearance and the aspect such as shaping all better.
As most preferably, described health food comprises active component and the auxiliary material of following weight portion:
Described health food comprises active component and the auxiliary material of following weight portion:
Present invention also offers a kind of preparation method of described health food, comprise the following steps:
(1) stock and adjunct is pulverized, sieve to obtain medicinal powder;
(2), after medicinal powder mixing step (1) obtained, granulate, obtain drug particles;
(3) drug particles that step (2) obtains is carried out compressing tablet on tablet press machine, obtain described health food.
As preferably, in step (1), described medicinal powder is crossed 80 mesh sieves and is obtained.
As preferably, in step (2), described method of granulating is that wetting agent carries out wet granulation for referring to purified water.
Compared with the existing technology, beneficial effect of the present invention is embodied in:
(1) in prescription of the present invention add colostrum basic protein fraction powder and calcium citrate there is mutually collaborative effect, the absorption efficiency of calcium can be improved significantly.
(2) by using sweet mellow wine and lactose as auxiliary material, make the taste of product and outward appearance and the aspect such as shaping all better, be convenient to take.
Detailed description of the invention
Embodiment 1
Prescription:
Aminoglucose hydrochloride 255g calcium citrate 525g
Chondroitin sulfate 150g colostrum basic protein fraction powder 22.5g
Sweet mellow wine 225g lactose 322.5g
Preparation method:
(1) pre-treatment: aminoglucose hydrochloride, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, lactose is for subsequent use after the assay was approved;
(2) sieve, weigh: weigh for subsequent use by formula ratio after qualified aminoglucose hydrochloride, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, lactose are crossed 80 mesh sieves respectively;
(3) mix: the aminoglucose hydrochloride of formula ratio, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, lactose are put in mixer mix 30 minutes mixed powder is for subsequent use;
(4) softwood processed, granulation, drying: purified water is added softwood processed in mixed powder, with 16 mesh sieve wet granulars, wet granular is dry, and baking temperature is 50 DEG C, is dried to moisture qualified;
(5) whole grain: dried particles is for subsequent use after crossing the whole grain of 16 mesh sieve;
(6) compressing tablet: above-mentioned particle is carried out compressing tablet, the heavy 1.5g/ sheet of sheet, tablet weight variation controls ± 5%, and per half an hour weighs once, obtains chewable tablets.
Embodiment 2
Prescription:
Aminoglucose hydrochloride 220g calcium citrate 300g
Chondroitin sulfate 100g colostrum basic protein fraction powder 16g
Sweet mellow wine 133g Icing Sugar 118g
Preparation method:
(1) pre-treatment: aminoglucose hydrochloride, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, Icing Sugar is for subsequent use after the assay was approved;
(2) sieve, weigh: weigh for subsequent use by formula ratio after qualified aminoglucose hydrochloride, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, Icing Sugar are crossed 80 mesh sieves respectively;
(3) mix: the aminoglucose hydrochloride of formula ratio, calcium citrate, chondroitin sulfate, colostrum basic protein fraction powder, sweet mellow wine, Icing Sugar are put in mixer mix 30 minutes mixed powder is for subsequent use;
(4) softwood processed, granulation, drying: purified water is added softwood processed in mixed powder, with 16 mesh sieve wet granulars, wet granular is dry, and baking temperature is 50 DEG C, is dried to moisture qualified;
(5) whole grain: dried particles is for subsequent use after crossing the whole grain of 16 mesh sieve;
(6) compressing tablet: above-mentioned particle is carried out compressing tablet, the heavy 1.5g/ sheet of sheet, tablet weight variation controls ± 5%, and per half an hour weighs once, obtains chewable tablets.
Comparative example 1
Comparative example 1 is not containing colostrum basic protein fraction powder, and the content of other medicinal materials is identical with embodiment 1 with preparation method.
Comparative example 2
The preparation method of comparative example 2 is identical with embodiment 1, and difference is that 300g calcium citrate replaces with calcium gluconae.
Performance test
1.1 animals used as test: the SPF level birth ablactation Wistar male rat of about 4 weeks selecting Shandong University's Experimental Animal Center to provide, body weight is 60 ~ 75g about.Animal used as test production licence number SCXK (Shandong) 20090001.Experimental situation temperature 22 DEG C ± 2 DEG C, relative humidity 50% ± 10%.The SPF level animal used as test environmental facility quality certification number is No. 20100011, Shandong rotating ring word SYXK (Shandong).After one week laundering period, fasting 12 hours, weighs, and according to body weight random packet, often organizes 10 rats, takes the health food of each embodiment and comparative example respectively.
1.2 dosage arrange and give mode with tested material: respectively organize and all feed low calcium basal feed (formula of low calcium basal feed used is as shown in table 1), drink deionized water.Per os once a day gavage gives tested material (i.e. the health food of each embodiment and comparative example), and the actual administered dose being converted to calcium is 216mg/kg.bw; Separately arrange calcium carbonate control group, calcium carbonate control group gives calcium carbonate 540mg/kg.bw (wherein calcic 40%, i.e. actual administered dose 216mg/kg.bw) every day, gives the indices testing bone substance density improving function after 3 months continuously.
Formula (the Ca of the low calcium basal feed of table 1
2+meter, 150mg/100g feed)
| Composition | ％ | Composition | ％ |
| Casein | 10.0 | Salt-mixture b | 2.6 |
| Analysis for soybean powder a | 15.0 | Mixed vitamin c | 1.0 |
| Wheat flour | 54.0 | Choline Chloride | 0.2 |
| Corn oil | 4.0 | Dl-methionine | 0.2 |
| Cellulose | 2.0 | Starch d | 11.0 |
Note:
aneed use after HIGH PRESSURE TREATMENT,
bsalt-mixture: each constituent content: KH in every kg salt-mixture
2pO
4501.4g; NaCl74.0g; MgCO
350.2g; Ferrous lactate 5.4g; Zinc lactate 4.16g; MnCO
33.5g; CuSO
4.5H
2o0.605g; Na
2seO
36.6mg; KI7.76mg; Cr
3cl6H
2o0.292g; With sucrose to 1kg.
cmixed vitamin: each constituent content in every kg mixed vitamin: vitamin A 400000IU; Vitamin D
3100000IU; Vitamin E 500IU; Vitamin K5 mg; Cobastab
1600mg; Cobastab
2600mg; Cobastab
6700mg; Cobastab
121mg; Niacin 3g; Folic acid 200mg; Calcium pantothenate 1.6g; Biotin 20mg; With sucrose to 1kg.
dstarch consumption can be regulated according to the expense of each group of tested material (or calcium carbonate).
1.3 key instruments and reagent: U.S. NORLAND-Stratec peripheral Dual-energy X-rays absorptionmetry (pDEXA), zootomy apparatus, animal balance, 105 DEG C of baking ovens, calcium carbonate standard liquid, potassium hydroxide, EDTA solution.
1.4 experimental technique
1.4.1 body weight determination: fasting, after 12 hours, measures body weight.Measure the weight of animals once weekly.
1.4.2 femur gravimetry: animal feeding was put to death after 3 months, separates right side femur, bakes to constant weight in 105 DEG C of baking ovens, weighs key heavy.
1.4.3 calcium content of bone and Calcium Content in Foodstuff measure
Low calcium basal feed sample, through Homogeneous phase mixing, is dried in an oven, is placed in drier and cools, and takes out grinding.Get femur on the right side of rat to dry to constant weight in 105 DEG C of baking ovens.Weigh key heavy, then pulverize, grind, digest.With calcium content in the low calcium basal feed of EDTA titration measuring and thighbone samples.Calcium content 146.0mg/100g in low calcium basal feed, meets requirement of experiment.
1.4.3 thighbone density measures: the bone density measuring left femur mid point and femur distal end with U.S. NORLAND-Stratec peripheral Dual-energy X-rays absorptionmetry.
1.5 experimental datas statistics: adopt SPSS statistical software to carry out comparing between the one-way analysis of variance of each experimental group and control group and group.
2 results
2.1 impacts on rat femur weight
Table 2 each treated animal femur weight (x ± s)
As shown in Table 2, during tested material with embodiment 1 and embodiment 2, the weight of femur is apparently higher than comparative example and calcium carbonate group.
2.2 impacts on rat stock calcium content
Table 3 each treated animal femur calcium content (x ± s)
As shown in Table 3, during tested material with embodiment 1 and embodiment 2, animal femur calcium content is apparently higher than comparative example and calcium carbonate group.
2.3 impacts on rat femur bone density
Table 4 each treated animal femur mid point bone density (x ± s)
Table 5 each treated animal femur distal end bone density (x ± s)
From the result of table 4 and table 5, during with the product of embodiment 1 and embodiment 2 for tested material, the bone density of femur is apparently higher than comparative example and calcium carbonate group.
Claims (10)
1. increase a health-care food composition for bone density, it is characterized in that, comprise the component of following weight portion:
2. health-care food composition as claimed in claim 1 is preparing the application in health food, it is characterized in that, described health food is used for prevention and improves osteoporosis.
3. health-care food composition according to claim 2 is preparing the application in health food, it is characterized in that, described health food is tablet, comprises active component and the auxiliary material of following weight portion:
4. health-care food composition according to claim 3 is preparing the application in health food, it is characterized in that, described filler is that the sweet mellow wine of 0.4 ~ 0.8:1 and lactose form by mass ratio.
5. health-care food composition according to claim 4 is preparing the application in health food, it is characterized in that, described health food comprises active component and the auxiliary material of following weight portion:
6. a preparation method for the health food as described in any one of claim 2 ~ 5, is characterized in that, comprises the following steps:
(1) stock and adjunct is pulverized, sieve to obtain medicinal powder, and medicinal powder is mixed;
(2) by the medicinal powder mixed that step (1) obtains, carry out granulation and obtain drug particles;
(3) drug particles that step (2) obtains is carried out compressing tablet on tablet press machine, obtain described health food.
7. the preparation method of health food according to claim 6, is characterized in that, in step (1), described medicinal powder is crossed 80 mesh sieves and obtained.
8. the preparation method of health food according to claim 6, is characterized in that, in step (2), method of granulating comprises wet granulation and dry granulation.
9. the preparation method of health food according to claim 8, it is characterized in that, in described wet granulation, with purified water or with the ethanol water of 50%-80% for wetting agent, with 16 or 18 mesh sieve wet granulars, wet granular is dried to moisture qualified after to sieve whole grain.
10. the preparation method of health food according to claim 8, is characterized in that, in described dry granulation, is put in dry granulating machine by medicinal powder and granulates, and the whole grain that sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446638.2A CN105105143A (en) | 2015-07-27 | 2015-07-27 | Health-care food composition capable of increasing bone density, health-care food and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446638.2A CN105105143A (en) | 2015-07-27 | 2015-07-27 | Health-care food composition capable of increasing bone density, health-care food and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105105143A true CN105105143A (en) | 2015-12-02 |
Family
ID=54653471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510446638.2A Pending CN105105143A (en) | 2015-07-27 | 2015-07-27 | Health-care food composition capable of increasing bone density, health-care food and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105105143A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288060A (en) * | 2018-09-27 | 2019-02-01 | 广东环凯微生物科技有限公司 | A kind of L MALIC ACID increases the health care product and preparation method thereof of bone density |
| CN109527590A (en) * | 2018-12-27 | 2019-03-29 | 安徽康博特保健食品有限公司 | A kind of basic protein protein powder of novel strong bone and preparation method thereof |
| CN111012900A (en) * | 2019-12-27 | 2020-04-17 | 黑龙江省完达山乳业股份有限公司 | Composition with function of increasing bone mineral density and preparation method and application thereof |
| CN111248445A (en) * | 2020-03-11 | 2020-06-09 | 北京康立生医药技术开发有限公司 | Composition containing lycium barbarum polysaccharide for increasing bone mineral density |
| CN114532530A (en) * | 2022-02-16 | 2022-05-27 | 浙江华方生命科技有限公司 | Colostrum glucosamine chondroitin calcium chewable tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
-
2015
- 2015-07-27 CN CN201510446638.2A patent/CN105105143A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288060A (en) * | 2018-09-27 | 2019-02-01 | 广东环凯微生物科技有限公司 | A kind of L MALIC ACID increases the health care product and preparation method thereof of bone density |
| CN109527590A (en) * | 2018-12-27 | 2019-03-29 | 安徽康博特保健食品有限公司 | A kind of basic protein protein powder of novel strong bone and preparation method thereof |
| CN111012900A (en) * | 2019-12-27 | 2020-04-17 | 黑龙江省完达山乳业股份有限公司 | Composition with function of increasing bone mineral density and preparation method and application thereof |
| CN111012900B (en) * | 2019-12-27 | 2023-09-19 | 北大荒完达山乳业股份有限公司 | Composition with bone mineral density increasing function and preparation method and application thereof |
| CN111248445A (en) * | 2020-03-11 | 2020-06-09 | 北京康立生医药技术开发有限公司 | Composition containing lycium barbarum polysaccharide for increasing bone mineral density |
| CN114532530A (en) * | 2022-02-16 | 2022-05-27 | 浙江华方生命科技有限公司 | Colostrum glucosamine chondroitin calcium chewable tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105105143A (en) | Health-care food composition capable of increasing bone density, health-care food and preparation method | |
| CN102318835A (en) | Composition for reducing bone loss and preparation method thereof | |
| CN102150836B (en) | Ammonia sugar peptide soft capsule | |
| CN102805858B (en) | High-efficiency calcium supplement capsule and preparation method thereof | |
| CN104705658B (en) | Health food with bone density improving function | |
| CN102552877A (en) | Health-care preparation for improving osteoporosis and increasing bone density and preparation method thereof | |
| CN103039976A (en) | Healthcare food for increasing bone density and preparation method thereof | |
| CN102551045B (en) | Collagen calcium tablet | |
| CN106729599A (en) | A kind of pharmaceutical composition for increasing bone density and its production and use | |
| CN104605226A (en) | Healthcare product with function of increasing bone mineral density | |
| CN107281218A (en) | A kind of high-selenium corn is combined calcium-supplementing preparation and preparation method thereof | |
| CN104146260A (en) | Health-care food for improving bone density and preparation method thereof | |
| CN106727676A (en) | A kind of replenish the calcium composition and its application for reducing hypercalcemia risk | |
| CN110214947A (en) | A kind of prevention and treatment osteoarthritis composition | |
| WO2018107324A1 (en) | Calcium supplement composition for decreasing risk of hypercalcemia and use thereof | |
| CN108968075A (en) | It is a kind of improve bone health composition and its application | |
| Goel et al. | In vitro binding of bile salt to rhubarb stalk powder | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| JP4463720B2 (en) | Chitosan / green leaf-containing water suspension composition with improved aggregation and precipitation | |
| CN105535944A (en) | Medical and edible composite health medicine for preventing and controlling osteoporosis and articular degeneration and preparation method of medical and edible composite health medicine | |
| CN109125269A (en) | A kind of scutelloside copper pre-mixing agent and preparation method thereof for treating grice diarrhoea | |
| JP2004535455A (en) | Calcium L-threonate for preventing or treating cartilage-related diseases | |
| CN109394808A (en) | A kind of ammonia sugar calcium piece and preparation method thereof increasing bone density | |
| CN110201023A (en) | A kind of prevention and treatment osteoporosis composition | |
| CN110478372B (en) | Composition for preventing and/or treating hyperuricemia/gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |